Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 824

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 824
---
 the terms and conditions of this Agreement [***].

2.4 Non-Compete.

(a) Scope. [***].

(b) Exclusions. Notwithstanding the foregoing in this Section 2.4:

(i) the provisions of Section 2.4(a) will not apply to such Acquirer of a Party that is Developing or Commercializing a Competing
Product as of the closing of such acquisition or commences Developing or Commercializing a Competing Product thereafter during the Term, provided that such Competing Product [***].

(ii) if,
during the Term, either Party or its Affiliate acquires a Third Party that is Developing or Commercializing a Competing Product, then the Development or Commercialization of such Competing Product will not constitute a breach of Section 2.4(a)
if such Party Affiliate [***].

(iii) Notwithstanding the foregoing provisions of this Section 2.4, WuXi Biologics or its Affiliates shall [***].

2.5 No Other Rights; Existing Relationships. As between the Parties, WuXi Biologics shall always retain ownership of all
Licensed IP. Except for the rights and licenses expressly granted in this Agreement, each Party retains all rights under its intellectual property, and no additional rights shall be deemed granted to either Party by implication, estoppel or
otherwise. For clarity, the Parties acknowledge that subject to Section 2.5, WuXi Biologics retains the right to Exploit any ADCs and products that are not a Competing Product. WuXi Biologics shall be solely responsible for, and Aadi will not
have any obligation or liability with respect to, all payment and other obligations that WuXi Biologics, its Affiliates or (sub)licensees may have under any agreement or understanding with any Third Party in effect prior to, as of, or after the
Effective Date that relates to the Licensed IP, or any Licensed ADC (or any component thereof) or any Licensed Product.

ARTICLE III

GOVERNANCE

3.1 Joint Steering Committee. Within [***] following the Effective Date, WuXi Biologics and Aadi shall establish a Joint
Steering Committee (“JSC”) to discuss and coordinate [***] in connection with this Agreement and otherwise provide a forum for the exchange of information with respect to the Development of Licensed ADCs and Licensed Products in the
Territory.

3.2 Role. The JSC shall:

(a) Provide a forum for each Party to keep the other Party reasonably informed